Ann: New Independent Trial Data Supports Potential of Veyonda, page-12

Zenox was across this news and posted the link to results of the WARMTH study on 26/5, way before the market announcement.

That's the value of this forum, great insights from posters, like Goldstar looking investigating who was behind the recent sell offs, or Zecs finds on the patent front, Rbx’s ongoing insights.

Not scrapping with Vrs. The scrapping that goes on about obvious weak arguments detracts from the discussions we could be having.

This company remains hopelessly undervalued just on prospects in treating prostate ca alone and ignoring the other 3 pillars, particularly when you consider there’s 30 mil cash and they own 10 mil worth of Nyrada. What are we going to do if it works in COVID/sepsis as well? Exciting times ahead.